Asia Pacific Obesity Treatment Market Size & Outlook

Name: Asia Pacific Obesity Treatment Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The obesity treatment market in Asia Pacific is expected to reach a projected revenue of US$ 3,105.0 million by 2030. A compound annual growth rate of 16.4% is expected of Asia Pacific obesity treatment market from 2025 to 2030.

Asia Pacific obesity treatment drug class outlook (Revenue, USD million, 2018-2030)
- GLP-1 Receptor Agonists
  - Semaglutide (Wegovy)
  - Liraglutide (Saxenda)
  - Tirzepatide (Zepbound)
- Lipase Inhibitors (Orlistat)
- Appetite Suppressants (Phentermine, Lorcaserin)
- Other Drug Class
Asia Pacific obesity treatment route of administration outlook (Revenue, USD million, 2018-2030)
- Parenteral
- Oral
Asia Pacific obesity treatment distribution channel outlook (Revenue, USD million, 2018-2030)
- Retail Pharmacies
- Hospital Pharmacies
- Other Distribution Channel

Asia Pacific Obesity Treatment Market Size & Outlook

Sign up - it's easy, and free!